Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study

Clinical trial NCT02113800 · COMPLETED

Trial details

NCT number: NCT02113800
Sponsor: AIO-Studien-gGmbH
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Poorly Differentiated Malignant Neuroendocrine Carcinoma Neuroendocrine Carcinoma, Grade 3 Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3 Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma] That Switched to G3 Neuroendocrine Tumor, Grade 3 and Disease Progression as Measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1.)

Start date: 2015-08-01
Primary completion: 2020-04-01
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.